Aptevo Therapeutics Announces APVO436 Monotherapy Is Active in Patients Who Have Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome
Science in Seattle,
Aptevo Therapeutics Inc., a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based…